US equities |
MU $1,045.56 ▲+0.00% INTC $112.50 ▲+0.00% NVDA $239.24 ▲+0.00% SNDK $1,660.46 ▲+0.00% SPCX $171.92 ▲+0.00% AMD $649.42 ▲+0.00% MRVL $287.01 ▲+0.00% AVGO $375.81 ▲+0.00%
FinancialContent

Articles published by Castle Biosciences, Inc.

< Previous 1 2 3 4 5 6 Next >
News headline image
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
News headline image
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
News headline image
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
News headline image
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
News headline image
Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
News headline image
Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
News headline image
Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
News headline image
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
News headline image
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
News headline image
Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
News headline image
Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
News headline image
Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
News headline image
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
News headline image
New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
News headline image
Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
News headline image
Castle Biosciences Reports Third Quarter 2025 Results
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
News headline image
Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
News headline image
Castle Biosciences to Participate in Upcoming Investor Conferences
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
News headline image
New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
News headline image
New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
News headline image
Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
News headline image
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
News headline image
Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
News headline image
Castle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
News headline image
New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
News headline image
New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
News headline image
Castle Biosciences to Participate in Upcoming Investor Conferences
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
News headline image
Castle Biosciences Reports Second Quarter 2025 Results
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
News headline image
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
News headline image
Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
< Previous 1 2 3 4 5 6 Next >